Developers could face surge in clinical trial lawsuits
A surge in early-stage drug testing could well set the stage for a spike in lawsuits from patients who feel they've been hurt by the drugs they're volunteering to test, says a new report in The Wall Street Journal. The article starts off with the lawsuit brought by the family of Suzanne Davenport, who says she was hurt by an experimental medication for Parkinson's. Plaintiffs generally have a hard time making these charges stick, particularly as it's often difficult to link any worsening in their condition to the drug rather than the disease. Plaintiffs attorneys, though, are seeing plenty of fresh opportunities in the drug testing arena.
- read the report from The Wall Street Journal
Related Articles:
Report: FDA lax in clinical trial oversight. Report
Financial conflicts raise questions over trial results. Report
Comments
I may have a solution to protect CROs and their drug company sponsors from this risk. It revolves around informed consent.
jmaeglin@aol.com
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


